Many companies in the biotech industry performed well last year. Two in particular stood out. Both saw their shares more than double in 2024, thanks to strong clinical progress. While these two drugmakers still don’t have any approved products on the market, both could still see above-average returns in 2025. Let’s look deeper at their prospects this year and beyond.
This post originally appeared at The Motley Fool.